Abstract: Two-dimensional (2D) crystals have renewed opportunities in artificial lattice design and assembly without the constraints of epitaxy. However, the lack of thickness control in exfoliated van der Waals (vdW) layers prevents realization of repeat units with high fidelity. Uniform, wafer-scale samples permits engineering of both electronic and optical dispersions in stacks of disparate 2D layers with multiple repeating units. Systems, methods, and devices present optical dispersion engineering in a superlattice structure including alternating layers of 2D excitonic chalcogenides and dielectric insulators. Examples demonstrate >90% narrowband absorption in <4 nm active layer excitonic absorber medium at room temperature, concurrently with enhanced photoluminescence in cm2 samples. These superlattices show evidence of strong light-matter coupling and exciton-polariton formation with geometry-tunable coupling constants.

Abstract: One aspect of the present invention relates to double-stranded RNA (dsRNA) agent capable of inhibiting the expression of a target gene. Other aspects of the invention relate to pharmaceutical compositions comprising these dsRNA molecules suitable for therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA molecules, e.g., for the treatment of various disease conditions.

Abstract: RNAi agents (e.g., CYP7A1 RNAi agents) for inhibiting the expression of the CYP7A1 gene, compositions including the RNAi agents conjugated to a targeting moiety, and methods of use are described. Also disclosed are pharmaceutical compositions including one or more RNAi agents (e.g., CYP7A1 RNAi agents). Delivery of the RNAi agent(s) to liver cells in vivo inhibits CYP7A1 gene expression and treats a CYP7A1 disease or a CYP7A1-associated disease.

Abstract: A hydrodesulfurization or hydrodenitrogenation catalyst, the hydrodesulfurization or hydrodenitrogenation catalyst comprising an amount of a composition, the composition comprising: a population of crystalline transition metal dichalcogenide platelets having the empirical formula MC2, wherein M is a transition metal and C is a chalcogenide, each of the platelets comprising a region of 2H phase and/or a region of 3R phase, and each of the platelets being characterized as comprising a single atomic layer to a few atomic layers.

Abstract: The present disclosure provides microbial consortia, and methods of making and using the same, comprising a complete microbiome replacement capable of stable engraftment in the gastrointestinal tract for the treatment of IBD, ulcerative colitis, and Crohn's disease.

Abstract: One aspect of the present invention relates to double-stranded RNA (dsRNA) agent capable of inhibiting the expression of a target gene. Other aspects of the invention relate to pharmaceutical compositions comprising these dsRNA molecules suitable for therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA molecules, e.g., for the treatment of various disease conditions.

Abstract: The present disclosure relates to implementing scrolling controls within a software application. More particularly, the present disclosure relates to methods and systems of mapping and translating inputs received from one or more controllers or user interfaces communicatively coupled to a computing system or device on which a software application is being executed, to one or more instructions or events for implementing a scrolling event that the software application is configured to recognize.

Abstract: One aspect of the instant application can provide a system and method for replacing a faulty or failing memory device during runtime. During operation, a host device of a plurality of coupled memory devices can detect an error-containing memory device and select, from a pool of standby memory devices, a replacement memory device. The host device can migrate data from the error-containing memory device to the replacement memory device during runtime of applications executing on the host device, replicate host physical address (HPA) address-mapping from the error-containing memory device to the replacement memory device, and replace the error-containing memory device with the replacement memory device.

Abstract: Provided are novel transition metal dichalcogenides having a platelet structure and comprising a 2H phase region and/or a 3R phase region. The platelets exhibit a narrow size distribution and comparatively high surface area and edge area, which characteristics render the platelets especially suitable for catalysis applications, as well as use in electronic devices. Also provided are methods of synthesizing the disclosed transition metal dichalcogenide platelets.

Abstract: RNAi agents (e.g., CYP7A1 RNAi agents) for inhibiting the expression of the CYP7A1 gene, compositions including the RNAi agents conjugated to a targeting moiety, and methods of use are described. Also disclosed are pharmaceutical compositions including one or more RNAi agents (e.g., CYP7A1 RNAi agents). Delivery of the RNAi agent(s) to liver cells in vivo inhibits CYP7A1 gene expression and treats a CYP7A1 disease or a CYP7A1-associated disease.

Abstract: A method for selective performing a validation in one or more technical operations by a cloud based validation framework is provided. The method includes identifying a job task to be performed, identifying technical operations associated with the job task; receiving user configurable input data for performing validation on at least one technical operation associated with the job task; and submitting the user configurable input data into the cloud network based validation framework. The method further includes determining, by the cloud network based validation framework, at least one technical operation specified for performing a validation function among the technical operations; generating a dictionary file for the at least one technical operation specified for performing the validation function; and performing the validation function specified by the dictionary file.

Abstract: One aspect of the present invention relates to double-stranded RNA (dsRNA) agent capable of inhibiting the expression of a target gene. Other aspects of the invention relate to pharmaceutical compositions comprising these dsRNA molecules suitable for therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA molecules, e.g., for the treatment of various disease conditions.

Abstract: One aspect of the instant application can provide a system and method for replacing a faulty or failing memory device during runtime. During operation, a host device of a plurality of coupled memory devices can detect an error-containing memory device and select, from a pool of standby memory devices, a replacement memory device. The host device can migrate data from the error-containing memory device to the replacement memory device during runtime of applications executing on the host device, replicate host physical address (HPA) address-mapping from the error-containing memory device to the replacement memory device, and replace the error-containing memory device with the replacement memory device.

Abstract: The present invention relates to a therapeutic oligonucleotide having a 5? and a 3? end and comprising a sequence of nucleosides linked together by inter-nucleoside linkages, wherein: at least one inter-nucleoside linkage is an amide linker moiety; at least one inter-nucleoside linkage is a phosphorothioate linker moiety; and at least one nucleoside present in the oligonucleotide is a locked nucleoside; wherein the at least one locked nucleoside is directly attached to the 3? end or the 5? end of the amide linker moeity.

Abstract: One aspect of the present invention relates to double-stranded RNA (dsRNA) agent capable of inhibiting the expression of a target gene. Other aspects of the invention relate to pharmaceutical compositions comprising these dsRNA molecules suitable for therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA molecules, e.g., for the treatment of various disease conditions.

Abstract: A data collection apparatus (10) and a computer-implemented data collection method (50) using the same are provided. The data collection apparatus (10) includes a first linear stage (12) and a second linear stage (14). A sample carriage (16) is attached to the first linear stage (12), the first linear stage (12) being operable to move the sample carriage (16) along a first axis. A probe carriage (18) is attached to the second linear stage (14), the second linear stage (14) being operable to move the probe carriage (18) along a second axis. A third linear stage (20) is attached to the probe carriage (18). In use, the third linear stage (20) is operable to receive a detachable characterisation probe (22) and to move the characterisation probe (22) along a third axis. A camera (24) is attached to the probe carriage (18). In use, the camera (24) is configured to capture an image of one or more samples on the sample carriage (16).

Abstract: The present invention provides a method for trimming a side portion of a pre-manufactured leading-edge protection element for a wind turbine blade. The element comprises a first side portion and a second side portion, the first side portion, when mounted to the wind turbine blade, extending from the leading edge and along a part of a pressure side of the wind turbine blade, and the second side portion, when mounted to the wind turbine blade, extending from the leading edge and along a part of a suction side of the wind turbine blade, or vice versa. The method comprises steps of: providing a support structure and a first cutting tool; arranging element on the support structure and fixating the element to the support structure, and cutting along a predetermined cutting path, whereby the leading-edge protection element is trimmed to a predetermined length. A corresponding system is also provided.

Abstract: In some examples, a system may include a first computing device communicatively coupled to a second computing device. Additionally, the first computing device is configured to obtain, from the second computing device, check-in data indicating an arrival of the user of the second computing device at a first location, and in response to obtaining the check-in data, determine current wait times. Moreover, the first computing device is configured to determine a first number of customers waiting for service, determine a first number of associates available to assist the first number of customers, and determine an expected wait time for the user operating the second computing device based at least on the current wait times. In some examples, the first number of customers waiting for service, and the first number of associates available. Further, the first computing device is configured to transmit the expected wait time to the second computing device.

Abstract: A method for providing test and regression automation via a cloud native elastic tool is disclosed. The method includes obtaining test configurations, the test configurations corresponding to a test suite; parsing the test configurations to identify testing conditions for the test suite; automatically determining testing parameters for executing the test suite based on the identified testing conditions; executing the test suite based on the automatically determined testing parameters in a computing environment, the computing environment including a distributed computing environment; verifying results of the executing; and generating a report for the test suite, the report including information that corresponds to the automatically determined testing parameters, an execution status, and a verification result.

Abstract: Two-dimensional (2D) crystals have renewed opportunities in artificial lattice design and assembly without the constraints of epitaxy. However, the lack of thickness control in exfoliated van der Waals (vdW) layers prevents realization of repeat units with high fidelity. Uniform, wafer-scale samples permits engineering of both electronic and optical dispersions in stacks of disparate 2D layers with multiple repeating units. Systems, methods, and devices present optical dispersion engineering in a superlattice structure including alternating layers of 2D excitonic chalcogenides and dielectric insulators. Examples demonstrate >90% narrowband absorption in <4 nm active layer excitonic absorber medium at room temperature, concurrently with enhanced photoluminescence in cm2 samples. These superlattices show evidence of strong light-matter coupling and exciton-polariton formation with geometry-tunable coupling constants.